Cat. No. | Product name | CAS No. |
DCAPI1388 |
Suplatast tosylate
Suplatast tosylate |
94055-76-2 |
DC9274 |
YM 90709
Featured
YM 90709 has been reported to be a selective inhibitor of interleukin-5 (IL-5). |
163769-88-8 |
DC29010 |
Sodium thiocyanate
Sodium thiocyanate reduces plasma levels of the pro-inflammatory cytokine IL-6, and increases the anti-inflammatory cytokine IL-10 levels. Sodium thiocyanate also significantly reduces of ROS formation. |
540-72-7 |
DC29153 |
Benralizumab
Featured
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma. |
1044511-01-4 |
DC29154 |
Dupilumab
Featured
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis. |
1190264-60-8 |
DC29155 |
Reslizumab
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively. |
241473-69-8 |
DC41390 |
Kaempferol 3-O-β-D-glucuronide
Kaempferol 3-O-β-D-glucuronide (Kaempferol-3-glucuronide), one conjugated kaempferol metabolite, has anti-inflammatory effect. Kaempferol 3-O-β-D-glucuronide significantly inhibits various pro-inflammatory mediators like IL-1β, NO, PGE2, and LTB4. Kaempferol 3-O-β-D-glucuronide upregulates the secretion of anti-inflammatory cytokine IL-10. |
22688-78-4 |
DC41586 |
AF12198
AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 μM) or the murine type I receptor (IC50>200 μM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and?blocks responses to IL-1 in vivo. |
185413-30-3 |
DC42461 |
Veledimex (S enantiomer)
Veledimex S enantiomer (INXN-1001 S enantiomer) is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate of and substrate for CYP3A4/5. |
1093131-03-3 |
DC46027 |
SDZ 224-015
SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM). |
161511-45-1 |
DC46037 |
LY3509754(IL-17A inhibitor 1)
Featured
IL-17A inhibitor 1 (example 24) is a IL-17A inhibitor, with IC50 values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells. |
2452464-73-0 |
DC46172 |
IL-17 modulator 3
Featured
IL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseases. |
2467731-88-8 |
DC46954 |
CVN03650(IL-17 modulator 4)
Featured
IL-17 modulator 4 is a prodrug of IL-17 modulator 1. IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator. |
2446803-65-0 |
DC47150 |
Lipoxin A4
Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM. |
89663-86-5 |
DC47194 |
IL-4-inhibitor-1
IL-4-inhibitor-1 (compound 52) is an IL-4 inhibitor, with an EC50 of 1.81 µM. |
1332184-63-0 |
DC47973 |
IL-17A modulator-2
IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC50 of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders. |
2748749-47-3 |
DC47974 |
IL-17A modulator-1
IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC50 of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders. |
2748749-29-1 |
DC48417 |
IL-17A inhibitor 2
IL-17A inhibitor 2 is an IL-17A inhibitor for treating psoriasis, rheumatoid arthritis, and multiple sclerosis. |
2452464-77-4 |
DC49051 |
IL-17 modulator 5
IL-17 modulator 5 (compound 26) is a IL-17 inhibitor, with an IC50 of 1 nM. |
2724206-27-1 |
DC50244 |
IL-17 modulator 6
IL-17 modulator 6 (compound 61) is a potent Interleukin 17 (IL-17) modulator (pIC50=9.1). IL-17 modulator 6 has the ability to inhibit IL-17 and can be used for the treatment of inflammatory and autoimmune diseases. |
2725869-16-7 |
DC70159 |
A-552
A-552 (A552) is a potent, small molecule antagonist of human IL-36γ, exhibits Ki of 31/54 nM in the human IL-36γ evoked CXCL1 release in human/mouse cellular assays.A-552 directly binds to human IL-36γ with IC50 of 67.6 nM measured by ITC, does not show affinity for either mouse IL-36γ, human IL-36α or IL-36β.A-552 attenuates human IL-36γ induced chemokine release in mouse plasma, and hIL-36γ induced inflammation in human 3D skin equivalents.A-552 is a novel first in class small molecule antagonist of the IL-36 signaling pathway that binds selective human IL-36γ and can dose-dependently inhibit IL-36γ induced production of proinflammatory cytokines from human and mouse cells. |
|
DC71014 |
C6 L-threo Ceramide
C6 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. C6 L-threo Ceramide significantly inhibits IL-4 production in T cells. Anti-allergic agents. |
189894-80-2 |